相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
Alasdair J. Coles et al.
MULTIPLE SCLEROSIS JOURNAL (2022)
Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity
Tobias Ruck et al.
BRAIN (2022)
Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
Steffen Pfeuffer et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2021)
Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis
L. Scappaticcio et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2020)
Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab
Heinz Wiendl et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
TSH RECEPTOR ANTIBODIES: RELEVANCE & UTILITY
George J. Kahaly et al.
ENDOCRINE PRACTICE (2020)
Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases
Cara L. Mack et al.
HEPATOLOGY (2020)
Development of Autoimmune Thyroid Disease in Multiple Sclerosis Patients Post-Alemtuzumab Improves Treatment Response
Alina Sovetkina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study
Tobias Ruck et al.
EBIOMEDICINE (2019)
Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)
Annette F. Okai et al.
NEUROLOGY AND THERAPY (2019)
Auto-immune hepatitis in a patient with multiple sclerosis treated with alemtuzumab
Souraya El Sankari et al.
ACTA NEUROLOGICA BELGICA (2018)
Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features
Nadia Pariani et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab
Mika Saarela et al.
NEUROLOGY (2018)
Longitudinal Characterization of Autoantibodies to the Thyrotropin Receptor During Alemtuzumab Therapy: Evidence that the Thyrotropin Receptor May Precede Thyroid Dysfunction by Many Years
Ilaria Muller et al.
THYROID (2018)
Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society
M. Vagberg et al.
ACTA NEUROLOGICA SCANDINAVICA (2017)
Alemtuzumab CARE-MS I 5-year follow-up Durable efficacy in the absence of continuous MS therapy
Eva Havrdova et al.
NEUROLOGY (2017)
Alemtuzumab CARE-MS II 5-year follow-up
Alasdair J. Coles et al.
NEUROLOGY (2017)
Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab
David Baker et al.
JAMA NEUROLOGY (2017)
Thyroid Autoimmunity: Role of Anti-thyroid Antibodies in Thyroid and Extra-Thyroidal Diseases
Eleonore Froehlich et al.
FRONTIERS IN IMMUNOLOGY (2017)
Warm Autoimmune Hemolytic Anemia
Rakhi Naik
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2015)
Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2015)
Graves' disease following immune reconstitution or immunomodulatory treatment: should we manage it any differently?
Anthony P. Weetman
CLINICAL ENDOCRINOLOGY (2014)
Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro
Evis Havari et al.
IMMUNOLOGY (2014)
Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis
Gilbert H. Daniels et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis
Laura Azzopardi et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Smoking and multiple sclerosis susceptibility
Anna Karin Hedstrom et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2013)
被撤回的出版物: World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects (Retracted article. See vol. 135, pg. 2149, 2021)
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation
Joanne L. Jones et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Jeffrey A. Cohen et al.
LANCET (2012)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alasdair J. Coles et al.
LANCET (2012)
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial
A. J. Coles et al.
NEUROLOGY (2012)
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
Cindy Neunert et al.
BLOOD (2011)
Significance of Prediagnostic Thyroid Antibodies in Women with Autoimmune Thyroid Disease
Susan Hutfless et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
M. Cossburn et al.
NEUROLOGY (2011)
Disability Progression in a Clinical Trial of Relapsing-Remitting Multiple Sclerosis
Richard A. Rudick et al.
ARCHIVES OF NEUROLOGY (2010)
Transcriptomic epidemiology of smoking: the effect of smoking on gene expression in lymphocytes
Jac C. Charlesworth et al.
BMC MEDICAL GENOMICS (2010)
Immune reconstitution syndrome and the thyroid
Anthony Weetman
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)
Joanne L. Jones et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Increased levels of (class switched) memory B cells in peripheral blood of current smokers
Corry-Anke Brandsma et al.
RESPIRATORY RESEARCH (2009)
Cigarette smoke extract induces thymic stromal lymphopoietin expression, leading to TH2-type immune responses and airway inflammation
Yuki Nakamura et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2008)
Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis
Alasdair J. Coles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis
AL Cox et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
Primary and secondary autoimmune neutropenia
F Capsoni et al.
ARTHRITIS RESEARCH & THERAPY (2005)
An overlapping etiology of rapidly progressive glomerulonephritis
GS Markowitz et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2004)
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
WI McDonald et al.
ANNALS OF NEUROLOGY (2001)
Heavy cigarette smoking is strongly associated with rheumatoid arthritis (RA), particularly in patients without a family history of RA
D Hutchinson et al.
ANNALS OF THE RHEUMATIC DISEASES (2001)
Risk factors for primary biliary cirrhosis in a cohort of patients from the United States
A Parikh-Patel et al.
HEPATOLOGY (2001)
分享论文
